BCLP Advises OrbiMed on Restructuring and Financing Agreement With Listed Company Poxel
October 10, 2024
October 10, 2024
ST. LOUIS, Missouri, Oct. 10 -- Bryan Cave Leighton Paisner, a law firm, issued the following news:
BCLP advised OrbiMed, a US life sciences investment fund specializing in monetizing patent licensing cash flows, on a complex restructuring and financing transaction. The deal resulted in a $50 million non-dilutive financing agreement to monetize part of the royalties from sales of TWYMEEG (R), a product of the listed biopharmaceutical company. Collaterals such as cash flows, patents . . .
BCLP advised OrbiMed, a US life sciences investment fund specializing in monetizing patent licensing cash flows, on a complex restructuring and financing transaction. The deal resulted in a $50 million non-dilutive financing agreement to monetize part of the royalties from sales of TWYMEEG (R), a product of the listed biopharmaceutical company. Collaterals such as cash flows, patents . . .